Shows
Medical Digest & Congress ReportAML Highlights from EHA 2025Professor Petya Apostolova shares her insights on the Acute Myeloid Leukemia highlights from the 2025 EHA Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:aml-highlights-eha-20252025-06-2707 minMedical Digest & Congress ReportManagement of Multiple Myeloma at EHA 2025Professor Evangelos Terpos shares his insights on the management of Multiple Myeloma at the 2025 EHA Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:management-multiple-myeloma-eha-20252025-06-2608 minMedical Digest & Congress ReportHighlights of Diffuse Large B-Cell Lymphoma at EHA 2025Professor Thomas Oellerich shares his insights on the highlights of Diffuse Large B-Cell Lymphoma at the 2025 EHA Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:highlights-diffuse-large-b-cell-lymphoma-eha-20252025-06-2610 minMedical Digest & Congress ReportMultiple Myeloma update at EHA 2025Professor Andrzej Jakubowiak shares his insights on multiple myeloma updates at the 2025 EHA Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:multiple-myeloma-update-eha-20252025-06-2509 minMedical Digest & Congress ReportALL Highlights from EHA 2025Professor Sebastian Giebel shares his insights on the Acute Lymphoblastic Leukemia highlights from the 2025 EHA Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:all-highlights-eha-20252025-06-2308 min
HealthTalk-podcastenEHA oppsummert: Endrer disse resultatene behandlingsstandarden i Norge?I denne episoden av HealthTalk-podcasten diskuterer vi Europas største hematologikongress – EHA 2025 i Milano – hvor vi møtte flere av Norges ledende eksperter innen blodkreft.Hans Anderssen og Lars Brock Nilsen oppsummerer høydepunktene fra kongressen og bringer deg eksklusive intervjuer med blant andre:Fredrik Schjesvold, leder ved Oslo MyelomatosesenterTobias Slørdahl, overlege ved St. Olavs hospitalStein-Erik Gullaksen, forsker ved Haukeland universitetssjukehusSigrid Skånland, forsker ved Oslo universitetssykehusHør episoden og få innsikt i:De sensasjonelle 100 % responsratene fra ny trispecifikk myelomatosebehandlingLangtidsdata fra CAR-T-studien CARTITUDE – og hva det betyr for g...2025-06-1931 min
Practice Point® CME Podcasts: Expert Discussions in Hematology™Episode 24 - Podcast from EHA 2024 - Advancements in Myelofibrosis From Pathophysiology to Personalized Treatment StrategiesThis podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA 2024) Hybrid Congress, June 13-16, Madrid, Spain.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector of the Center of...2025-01-2016 min
Practice Point® CME Podcasts: Expert Discussions in Hematology™Episode 23 - Podcasts in Advanced Newly Diagnosed Multiple Myeloma: Updates from EHA 2024This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioPeter Voorhees, MDClinical Professor, Hematology and OncologyWake...2025-01-2023 min
Practice Point® CME Podcasts: Expert Discussions in Hematology™Episode 22 - Podcasts in Pediatric ITP - Advancements in Pediatric ITP Management: Insights from EHA 2024Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the EHA 2024 Hybrid Congress, June 13-16, Madrid, Spain.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025...2025-01-2013 min
The EMJ Podcast: Insights For Healthcare ProfessionalsHema Now: Episode 3: Reflections on the EHA CongressIn this episode of Hema Now, Dr. Jonathan Sackier welcomes Professor Antonio Almeida, a leader in hematology and the 2024 President of the EHA. They delve into the highlights from this year’s EHA Congress, discuss the founding of the Católica Medical School, and explore the transformative role of AI in healthcare. Timestamps: (00:00) -Introduction (01:40) -Reflection on the EHA 2024 Congress (06:10) -Approaches for future congresses (10:30) -Proudest accomplishments and EHA education initiatives (17:00) -Reflections on the treatment landscape of blood-related conditions (26:00) -Importance of registries in uncovering more about these diseases 2024-10-2944 min
LARVOL Onco Data PodcastLARVOL Onco Data Podcast | Deep Dive into EHA with Christian Hayden | E.23Deep Dive: Post-EHA 2024 Analysis | Join us for a special podcast featuring LARVOL's Mark Gramling in conversation with Christian Hayden, Director at Opus Strategy, LLC, as they take a deep dive into the recent European Hematology Association (EHA) conference. 🔍 EHA Insights: Gain insights into the key takeaways and groundbreaking research presented at EHA. Christian Hayden and Mark Gramling will explore the most significant advancements and their potential impact on hematology. 💡 Analysis: Christian Hayden brings his strategic expertise to the discussion, providing analysis and perspectives on the trends and developments in hematology research. 🌐 Implications for Practice: Discover how the findings from EHA can b...2024-10-0716 min
touchPODCASTTargeting BCMA in multiple myeloma: Insights from COMy and EHA 2024touchCONGRESS for touchONCOLOGY
Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice.
Overview
Data reviews with Prof. Mateos,
Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below
Clinical themes
Approved indications for BCMA-targeting agents,
New app...2024-10-0757 mintouchPODCASTTargeting BCMA in multiple myeloma: Insights from COMy and EHA 2024touchCONGRESS for touchHAEMATOLOGY
Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice.
Overview
Data reviews with Prof. Mateos,
Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below
Clinical themes
Approved indications for BCMA-targeting agents,
New app...2024-10-0757 mintouchPODCASTInsights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?touchCONGRESS for touchONCOLOGY
Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.
Overview
Data reviews with Dr McDonald
Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below
Clinical themes
How does IT...2024-09-0553 mintouchPODCASTInsights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?touchCONGRESS for touchHAEMATOLOGY
Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.
Overview
Data reviews with Dr McDonald
Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below
Clinical themes
How does IT...2024-09-0553 min
VJHemOnc PodcastUpdates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needsToday’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in sickle cell disease (SCD) and thalassemia from the 29th Congress of the European Hematology Association (EHA), held in Madrid, Spain.
The experts share key trial updates, including the Phase I/II RUBY trial (NCT04853576) of renizgamglogene autogedtemcel (reni-cel) for SCD, and the Phase III ENERGIZE trial (NCT0...2024-08-0511 min
OnkoImpulsTeaser: EHA 2024 Update zur AML Interview zum EHA 2024 und einem Studienupdate zur Akuten Myeloischen Leukämie (AML) mit Prof. Dr. Christoph Röllig, Bereichsleiter der Hämatologie und klinischen Studien in der Fachabteilung Hämatologie, Zelltherapie und medizinische Onkologie am Universitätsklinikum Carl Gustav Carus Dresden. Der Experte spricht über die Rolle der molekularen Diagnostik sowie verschiedenen neuen Therapieformen zur Behandlung der AML. ' Ganze Folge hörbar unter: https://www.krebsgesellschaft.de/onko-internetportal/kongresse/eha/2024/podcast-eha-2024-mit-update-zur-aml.html 2024-07-2501 minVJHemOnc PodcastThe role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024The introduction of Bruton’s tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024.
Tune in as Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, Tycel Phillips, MD, City of Hope, Duarte, CA, Chan Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share in...2024-07-2212 min
ScienceLinkLo mejor en los congresos ASCO y EHA 2024La Dra. Nidia Zapata, hematóloga en la Ciudad de México, México, nos comenta sobre lo más destacado presentado en los Congresos de ASCO y EHA del presente año, resaltando los siguientes estudios:
Congreso ASCO 2024:
Linfomas de células B:
• EPCORE NHL-1
Mieloma múltiple:
• IMROZ
Leucemia linfocítica crónica:
• Poster 7050
• CELESTIAL-TNCLL
Congreso EHA 2024:
Leucemia mieloide aguda:
• AUGMENT-101
Leucemia linfocítica aguda:
• HOVON- 146
Mieloma múltiple:
...2024-07-0821 minVJHemOnc PodcastUpdates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Meeting and the 29th Congress of the European Hematology Association (EHA).
You will hear from Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, who discusses updated data from the MagnetisMM-3 trial (NCT04649359) of elranatamab and real-world findings from a French compassionate use program using this agent. Rahul Banerjee, MD...2024-07-0816 min
Blood Cancer TalksEpisode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria IacoboniIn this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCLhttps://library.ehaweb.org/eha/2024/eha2024-congress/4136516 2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):https://library.ehaweb.org/eha/2024/eha2024-congress/422343 3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abst...2024-07-0647 minVJHemOnc PodcastUpdates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and moreIn today’s VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, who will discuss combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in the t...2024-07-0112 min
Oncology On The GoEnsuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024At the 2024 European Hematology Association (EHA) Congress, CancerNetwork® spoke with a variety of experts in the hematologic oncology space about optimizing outcomes across different patient populations and subgroups based on updated research they presented at the meeting.
Manali Kamdar, MD, an associate professor of medicine-hematology and clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus, in Colorado, spoke about data from the phase 1 TRANSCEND NHL 001 trial (NCT02631044) supporting the use of lisocabtagene maraleucel (liso-cel; Breyanzi) in earlier lines of therapy for patients with relapsed/refractory mantle cell lymphoma (MCL).1
Specifically, Kam...2024-06-2408 minMedical Digest & Congress ReportHaematology is at the forefront - interview with EHA PresidentWe asked Professor Antonio Almeida, the President of European Hematology Association about the benefits and perspectives in EHA as a European hematologist, about the highlights of this year EHA congress and about the new Guidelines.
Video: https://medicaldigest.org/scientific-contents/standalonecontent:haematology-forefront-interview-eha-president2024-06-1117 min
Puuduta Mind324. SAADE: Nõid Eha: kaitse end ruunimärkidega ning lõpuks saad seda, millest oled eluaeg unistanudMüstilistele ja vahel ka maistele teemadele pühendunud saates „Puuduta mind“ on seekord külas nõid Eha ehk selgeltnägijate seas tuntud ka kui Witch Eha. Ta on tegelenud esoteerikaga juba neli aastakümmet ning aidanud inimestel leida lahendusi nende probleemidele, kasutades selleks iidseid tarokaarte, ruune või pendlit. Seekord teemegi nende vidinate õigeks kasutamiseks korraliku koolituse.
Enamasti tullakse Witch Eha vastuvõtule alles siis, kui inimeste elus on juba toimunud ebameeldivad sündmused, ning otsitakse abi tagajärgede likvideerimiseks. Nõid Eha sõnul on palju tõhusam probleemi ennetada juba eos. Parim võimalus selleks on ennast laadida ja k...2024-05-2847 min
Indiana Sports Talk Podcast10:00PM-11:00PM - (David Eha, Tanner Camp, Kurt Darling) - 2/3/2024After a 5 minute score by Nathaniel Finch, David Eha recaps some college basketball action. Eha covers Ball State for the Ball State Network, and the Cardinals won 76-67 over Western Michigan. Tanner Camp of The Region Radio Sports Network joins Coach to talk about Marquette Catholic’s win over Triton. Kurt Darling of Nine Star TV calls in to recap some more boys basketball. Darling gives a rundown of the Tipton 60-46 win over Shenandoah. Dave Sockel of Southern Indiana Sports Productions turns the focus back on Girls’ Sectionals. He covered the Bedford North Lawrence 43-39 win over Jennings Coun...2024-02-0443 min
Passage to Profit Show - Road to EntrepreneurshipEntrepreneur Reveals Viking Beauty Secrets for Radiant Skin with Eha UrbsaluRichard Gearhart and Elizabeth Gearhart, co-hosts of The Passage to Profit Show along with Kenya Gipson interview Eha Urbsalu from Viking Beauty Secrets.
Join us as we delve into the world of Viking Beauty Secrets with Eha Urbsalu, hailing from Estonia, she shares the centuries-old skincare wisdom inspired by Nordic super antioxidants and vitamin-rich berries. Unveiling the magic of ingredients like seaboktorin, cloud berries, and rovenberries, we explore how these elements, once cherished by ancient Vikings, now form the backbone of a revolutionary skincare brand. From the rejuvenating powers of Icelandic volcanic sand to the v...2024-02-0108 min
EHA UnpluggedEHA Unplugged: MDS Classification and Risk AssessmentIn this episode, Prof Maria Teressa Voso talks about MDS classification and risk assessment. She explains the different risk scores, the importance of molecular genetics in classification, risk stratification and management in MDS patients. Guest: Prof Maria Teressa Voso ; Host: Dr Enrica OrsiniWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to...2023-08-0415 minVJHemOnc PodcastCLL highlights at EHA 2023: latest advances with the use of BTK inhibitorsBruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent agents being explored. There are several questions surrounding the sequencing and selection of these agents, and clinical trials exploring their efficacy. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, and Othman-Al Sawaf, MD, University Hospital of Cologne, Cologne, Germany, who dis...2023-06-2914 minVJHemOnc PodcastMyeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practiceIn recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refractory (R/R) disease. Several clinical trials are evaluating the efficacy of CAR-T cells and are further exploring the possibility of bringing these agents into earlier lines of therapy. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Jesús San Miguel, MD, University of Navarra, Pamplona, Spain, and Enrique Ocio, MD, PhD, Marqués d...2023-06-2208 minVJHemOnc PodcastLymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity managementThe treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and CAR-T cells demonstrating promising results. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Gloria Iacoboni, MD, Vall d’Hebron University Hospital, Barcelona, Spain, and Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who share some insights into recent advances in CAR-T therapy and bispecific antibodies in the treatment of LBCL. To...2023-06-1616 min
Na prahu zmienNa prahu zmien 224 - 2023-06-12 Adam ŘeháčekAdam Řeháček – stomatolog, malíř a muzikant.
Adam Řeháček si bude v rozhovoru s bývalým policejním prezidentem a předsedou Asociace nezávislých médií Stanislavem Novotným povídat o české stomatologické péči, výtvarném umění, hudbě i politické situaci doma i v zahraničí.2023-06-122h 08
From Persona To PersonalA Great Customer Experience Doesn't Always Start With the Customer With David Eha, Director of National Accounts at Restaurant TechnologiesDavid Eha is the Director of National Accounts at Restaurant Technologies (RT). With 25 years in the restaurant business, he is responsible for developing new partnerships with industry leaders and national restaurant chains to provide automated systems for some of the worst back-of-the-house processes. In his role, David takes the lead in implementing RT’s Total Oil Management solution, which allows its clients to run cleaner, smarter, safer, and more efficient operations — RT’s overriding objective. RT’s clients include McDonald’s, KFC, Wendy’s, Applebee’s, and Texas Roadhouse, to name a few. What you’ll learn in this episode:2023-05-2527 min
The BSH Guidelines Official PodcastEHA 2022: The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice PaperGuideline session at EHA Conference 2022 on The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper
2022-12-2145 minEHA UnpluggedPapers Unplugged: EHA and War in UkraineWhat can a not-for-profit NGO do for patients in a time of war? Join our guests, Prof Konstanze Döhner, Prof Elizabeth Macintyre, and Dr Nathalie van Havre as they discuss what the European Hematology Association (EHA) has done in favor of Ukraine and the Ukrainian hematological community. Our guests talk about support programs EHA has implemented and the obstacles that came with that. Prof Macintyre furthers the discussion by expressing her views on the role of medical organizations such as EHA in a crisis. This discussion is based on t...2022-11-1112 min
Demon TimeEpisode 3 - Water BoyBack at it again with the sizzling hot takes. The fantastic four take Fantasy Football (1:30) by the horns first. Waiver Wire picks, Buy Lows, and blown games fill this section to the brim. Can Week 10 get any worse for the EHA League? Our NFL (21:05) section keeps things spicy, just like the upsets last week. It's too early to tell, but who is the game predictor guru? CFP (44:27) wraps things up per usual. Something interesting is a brewing... PS: If our Guest Speaker Alan is listening, try to be here next week, bud. Thanks for listening!
---
Support this...2022-11-0956 min
Hämatologie Shortcasts#4 Hämatologische Highlights vom EHA in Wien 2022In der heutigen Folge besprechen wir die Hämatologischen Highlight vom EHA (European Hematology Association) in Wien 2022. Was gibt es Neues für die Anwendung in der täglichen Praxis? Themen:CLLMDSMultiples MyelomAMLALLHodgkinNicht maligne hämatologische ErkrankungenCMLIndolente Lymphome Sie möchten CME Punkte sammeln? Melden Sie sich auf https://www.hämatologie-shortcasts.de/4-haematologische-highlights-vom-eha-in-wien-2022.html an und laden Sie die PDF bitte herunter, füllen diese aus und übermitteln diese bitte an uns.Sie haben Fragen, Anmerkungen oder Kritik? Senden Sie uns eine Mail an info@ng-akademie.de.
2022-10-051h 21touchPODCASTHigher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022touchCONGRESS for touchONCOLOGY
Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel).
OVERVIEW
Data review with Dr Oliva (0:00)
Expert interviews with Prof. Heuser, Dr Ofran and Dr Oliva, answering the questions below
INTERVIEW QUESTIONS
Based on data presented at EHA 2022, which emerging treatments are most likely to impact f...2022-08-1656 minVJHemOnc PodcastMyeloma treatment updates from EHA 2022While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presented, with a large focus being placed on clinical trials and novel immunotherapies.
In this exclusive podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key advances in...2022-08-0313 min
VJHemOnc PodcastMyeloma treatment updates from EHA 2022While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presented, with a large focus being placed on clinical trials and novel immunotherapies.
In this exclusive podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key advances in...2022-08-0313 min
AyurGlow - harmoninen elämä36. Hiustenhoito - vieraana Eha VakkermanPodilinjoille on saapunut pitkästä aikaa asiantuntija vieras, kun aiheenamme on hiustenhoito! Luonnonkosmetiikan ja kasvivärien kanssa työskentelevä Eha Vakkerman kertoo, miten helliä hiuksia luonnollisin keinoin hyödyntäen ayurvedisia yrttejä.Millä tavoin teenäkin tunnettua Hibiskusta voi hyödyntää hiustenhoidossa?Mitä ayurvedista yrttiä Eha hyödyntää, niin hiusten hoitoon kuin koiran turkin pesuun?Mikä hiustenhoitorutiini tekisi erityisen hyvää Suomalaisille hennoille hiuksille?Jaksossa Eha jakaa myös vinkit elinvoimaisten hiusten saavuttamiseen sekä tärkeimmät askelmerkit, joiden avulla saavuttaa onnistunut hiusten kasvivärjäys kotioloissa.✨ Seuraa AyurGlowta Ins...2022-06-0239 min
Nedělní pohádky pro radostRok a jeho měsíce - díl 20. - Dubnové přeháňkyZačíná pršet a Jaro s vílou Sedmikráskou vchází do vodních tkalcoven. Tam si tkalci pochvalují jemné mráčkové plátno a švadlenky se trošku bojí, aby se neprotrhlo. Nejdříve vše vypadá v pořádku, ale nakonec bude přece jen potřeba usoukat mlhovinu o trošku pevnější. Aby zatím příroda nepřišla o vytoužený déšť, pustí se do práce konvičkářky. Že je neznáte? Nevadí. Pojďte si poslechnout dnešní jarní díl a brzy zjistíte, jak s dubnovými přeháňkami pomohou.2022-04-0907 min
DVTVLucie: Naplnily se nám pubertální sny, devadesátky byly velká party a bezbřehá naděje. Medvídka zákaz katapultoval v hitparádáchDevadesátky byly porevoluční party, bezbřehá naděje a entuziasmus. Některý historky nejsou publikovatelný. Počty koncertů v roce 1989 a 1990 byly tak enormní, že se to nedalo vydržet, proto jsme se poprvé rozpadli. Vždycky jsme se k sobě ale vrátili, funguje nám to, jsme už tolerantnější. Že budeme hrát v roce 1995 před Rolling Stones, to bychom předtím nikomu nevěřili, říkají členové kapely Lucie David Koller, P.B.Ch. a Michal Dvořák. Robert Kodym se rozhovoru nemohl zúčastnit. Videoklip k písni Medvídek Nova zakázala, to ji katapultovalo na přední m...2021-12-2906 min
Keeping the Nostalgia Alive Show!An Interview with Ball State Cardinal David EhaHoops Color Analyst and Ball State Cardinal David Eha shares his love an excitement for the game of basketball!
---
Send in a voice message: https://podcasters.spotify.com/pod/show/ktna/message2021-12-1850 min
Podcast Halo BandungBi Eha dan Mang Udin Masuk Top 45 Inovasi Jabar Tahun 2021Dinas Kependudukan dan Pencatatan Sipil (Disdukcapil) Kota Bandung kembali menorehkan prestasi dalam pemberian pelayanan publik kepada masyarakat melalui program inovasinya, yaitu layanan Bi Eha (Bisa Euy Hebat) dan Mang Udin (Mangga Urus Indentitasna). Apa itu Bi Eha dan Mang Udin? Dan seperti apa pelayanan kependudukan di Disdukcapil Kota Bandung di tengah pendemi Covid-19?--- Send in a voice message: https://anchor.fm/podcast-halo-bandung/message2021-10-1332 min
Tribun JabarLayanan Bi Eha dan Mang Udin, Apa Itu? | GOVERNMENT TALKPelayanan Administrasi Kependudukan bagi Disabilitas dan ODGJ melalui Inovasi BI EHA dan MANG UDIN.
Inovasi Disdukcapil Kota Bandung Bi EHA dan MANG UDIN masuk Top 45 Kompetisi Inovasi Jawa Barat (KIJB) Tahun 2021.
Ikuti perbincangan kami bersamaKepala Disdukcapil Kota Bandung dalam acara Government Talk.
Acara tersebut live di Youtube TribunJabar Video dan Facebook TribunJabar.id, Senin (4/10/2021) pukul 10.00.
Jangan lupa saksikan acaranya.
@disperindag_jbr @disdagin_bdg @ellywasliah
➖➖➖➖➖➖➖➖➖➖➖➖
💗like 💬comment 🔄share 👥tag
➖➖➖➖➖➖➖➖➖➖➖➖
Penyunting Gambar: ARA
Ayo kita ikuti protokol kesehatan, agar pandemi ini...2021-10-1144 minVJHemOnc PodcastEHA 2021: antibody therapies for NHLAntibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research interest in antibody-based therapeutic approaches. The use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies are increasingly being investigated in clinical trials for the treatment of NHL, particularly in diffuse large B-cell lymphoma (DLBCL) and in the relapsed/refractory setting, offering alternative strategies for disease management.
In this podcast, Gilles Salles, MD, PhD, of the Memorial Sloan Kettering, New York, NY, Martin Hutchings, MD, PhD, of the Copenhagen University Hospital...2021-09-1017 minVJHemOnc PodcastEHA 2021: antibody therapies for NHLAntibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research interest in antibody-based therapeutic approaches. The use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies are increasingly being investigated in clinical trials for the treatment of NHL, particularly in diffuse large B-cell lymphoma (DLBCL) and in the relapsed/refractory setting, offering alternative strategies for disease management.
In this podcast, Gilles Salles, MD, PhD, of the Memorial Sloan Kettering, New York, NY, Martin Hutchings, MD, PhD, of the Copenhagen University Hospital...2021-09-1017 minVJHemOnc PodcastEHA 2021: updates on novel agents for AMLA significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.
In this podcast, Andrew...2021-09-0815 minVJHemOnc PodcastEHA 2021: updates on novel agents for AMLA significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.
In this podcast, Andrew...2021-09-0815 minVJHemOnc PodcastEHA 2021: targeted therapies for ALLGreat progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. The use of targeted therapies has significantly improved survival outcomes for patients with ALL and has become a mainstay of frontline treatment. Since the FDA approval of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, clinical trials have been increasingly investigating combination regimens with these targeted agents with the goal of optimizing their use and reducing the need for cytotoxic therapies.
In today’s podcast, Bijal Shah, MD, of the H. Le...2021-09-0123 minVJHemOnc PodcastEHA 2021: targeted therapies for ALLGreat progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. The use of targeted therapies has significantly improved survival outcomes for patients with ALL and has become a mainstay of frontline treatment. Since the FDA approval of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, clinical trials have been increasingly investigating combination regimens with these targeted agents with the goal of optimizing their use and reducing the need for cytotoxic therapies.
In today’s podcast, Bijal Shah, MD, of the H. Le...2021-09-0123 minVJHemOnc PodcastEHA 2021: real-world data on myeloma, lymphoma and CLLReal-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies have been restricted to randomized clinical trials as their only form of testing a treatment; however, due to technological advancement, there are now ways in which data from real-world treatment settings can be collected by clinical researchers. Real-world data is used to support decision making regarding the usage, overall benefits, and risks associated with specific drugs and therapeutic combinations.
In this podcast, David Miklos, BSc, MD, PhD, of Stanford University, Stanford, CA, Elena Zamagni, MD, PhD, of...2021-08-2514 minVJHemOnc PodcastEHA 2021: real-world data on myeloma, lymphoma and CLLReal-world data gained through scientific studies is essential in the advancement of treatments for all hematologic malignancies. Historically, pharmaceutical companies have been restricted to randomized clinical trials as their only form of testing a treatment. However, due to technological advancement, there are now ways in which data from real-world treatment settings can be collected by clinical researchers. Real-world data is used to support decision making regarding the usage, overall benefits, and risks associated with specific drugs and therapeutic combinations.
In this podcast, David Miklos, BSc, MD, PhD, of Stanford University, Stanford, CA, Elena Zamagni, MD, PhD, of...2021-08-2514 minVJHemOnc PodcastEHA & ICML 2021: updates in Hodgkin lymphomaAlthough classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events, impacts on quality of life and poor outcomes in older patients present ongoing unmet needs. Much research is currently focused on risk stratification, such as with positive emission tomography (PET) scans, to identify patients who are at low- or high-risk of recurrence and enable the use of risk-adapted approaches. Furthermore, longer-term follow-up data from trials of novel immunotherapy combinations in the frontline setting have recently been presented which demonstrate durable remissions and may reduce the risk of relapse...2021-08-0612 minVJHemOnc PodcastLatest transplant updates from EHA 2021Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease (GvHD) is a systemic disorder that arises when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. Its occurrence poses a major medical complication that limits the efficacy of HSCT and causes significant morbidity and mortality. New insights into the pathophysiology of GvHD have led to new developments in treatment strategies. Additionally, immediate survival is no longer the only concern after allogeneic HSCT (allo-HSCT). The burden of long-term morbidity borne by allo...2021-08-0416 minVJHemOnc PodcastThe Lymphoma Sessions: highlights from EHA and ICML 2021In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD, Medical College of Wisconsin, Brookfield, WI; Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria; Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, review the most exciting updates in lymphoma from the 2021 European Hematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) meetings, highlighting the latest data on antibody, cellular and novel therapies.
The post The Lymphoma Sessions: highlights from EHA and ICML 2021 appeared first on VJHemOnc.
2021-07-3048 minVJHemOnc PodcastThe CLL Sessions: highlights from EHA and ICML 2021In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University of California Irvine, Irvine, CA; Lydia Scarfò, MD, Università Vita-Salute San Raffaele, Milano, Italy and Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, review the most exciting updates in chronic lymphocytic leukemia (CLL) from the 2021 European Hematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) meetings, including the latest data from the RESONATE-2, CLL14, MURANO and ELEVATE-RR trials, as well as talking on second-generation BTKs and fixed-duration therapy.
The post The CLL Sessions: highlights from...2021-07-2736 minVJHemOnc PodcastEHA 2021: updates on treatment for MDSMyelodysplastic syndromes (MDS) are a group of myeloid clonal disorders caused by a defect in bone marrow, which hinders their ability to produce healthy and normal functioning red blood cells. The heterogeneous nature of MDS means therapeutic approaches need to be specifically tailored to each subtype. Current treatment options for MDS include allogeneic hematopoietic stem cell transplantation, which is the only curative form of treatment and available to only a small population of patients, whilst for most patients, non-curative treatment such as iron chelation and growth factors, lenalidomide and hypomethylating agents are the only available options. Although progress has...2021-07-2612 minMedical Digest & Congress ReportNovelties in the treatment of Multiple Myeloma - report from EHA 2021Prof. Enrique Ocio give us a brief overview about the main messages of the studies presented on EHA 2021 regarding multiple myeloma.
Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-multiple-myeloma_eha_20212021-07-2607 minMedical Digest & Congress ReportNovelties in the treatment of follicular lymphoma - report from EHA 2021Prof. Kai Hübel speaks about the latest news came out from the EHA meeting in the field of follicular lymphoma treatment.
Video: https://congressreport.eu/scientific-contents/interview:novelties-treatment-follicular-lymphoma-eha20212021-07-2613 min
Oncology Knowledge into Practice PodcastHaematology series | ASCO/EHA highlights continued…In this episode we speak with Dr Navel Daver, Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA, to get his thoughts on the highlights of ASCO and EHA for patients with MDS and AML.
Funding Statement:
This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty2021-07-2317 minVJHemOnc PodcastThe Myeloma Sessions: key highlights from EHA and ASCO 2021The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients with multiple myeloma over the past decade. Despite this, many patients become relapsed or refractory to currently available therapies and as such, novel agents and combination regimens remain key to improving the outcomes of patients in high-risk subgroups. Immunotherapies, such as monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapies have become increasingly prominent in the multiple myeloma space, with the first CAR-T therapy for myeloma receiving FDA approval in March 2021. However, with such a broad range of treatments...2021-07-2141 minVJHemOnc PodcastEHA 2021: key trial updates in myelofibrosisThe breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led to a broadened range of treatment options across the spectrum of MPNs. Myelofibrosis is one of the most common types of MPN and many clinical trials are exploring novel drugs and combinations for its treatment. The JAK inhibitor ruxolitinib became the first JAK inhibitor to receive FDA approval for the treatment of myelofibrosis in 2011, and more recently the FDA granted approval to fedratinib for patients with intermediate-2 or high-risk myelofibrosis.
In this podcast, Srdan Verstovsek, MD, from...2021-07-2007 minVJHemOnc PodcastThe MPN Sessions: highlights from EHA and ASCO 2021Over the past decade there has been a vast increase in the number of clinical trials taking place in the field of myeloproliferative neoplasms (MPNs), with many trials investigating the potential benefits of novel JAK inhibitors both as monotherapy and in combination with other drugs, such as Bcl-2, Bcl-xL or BET inhibitors. More recently, next-generation sequencing has led to the identification of further mutations associated with MPNs, which may provide alternative therapeutic targets. In particular, the telomerase inhibitor imetelstat and the MDM2 inhibitor KRT-232, have demonstrated potential benefits for patients with myelofibrosis, whilst the tyrosine kinase inhibitor avapritinib recently...2021-07-1629 min
Iga naine on luguEha Urbsalu: Ma olen kui kaheksajalg!Eha Urbsalu alustas oma teekonda 80ndate lõpul, kus muusikakoolis ja näiteringis käinud noor naine unistas saada näitlejaks. Teekond selle unistuseni kulges läbi mitmete õnnestumiste ja läbipõlemiste. Oskus enda eest seista ja öelda enda kõrval seisvatele inimestele välja oma arvamus kasvas vaikselt, sest nii mõnigi usalduse pälvinud inimese negatiivne kommentaar röövis väliselt särava, kuid seest katki tehtud naise rahulolu iseendaga. Kõrghariduse omandamine ja oskus endas leida tasakaal on teinud tänaseks temast õnnelikuima naise maailmas. "Mitte kunagi pole hilja alustada " kinnitab Eha mitmel korral intervjuu ajal.2021-07-1653 minVJHemOnc PodcastThe MDS Sessions: highlights from ASCO/EHA 2021Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not replicated in this space. Aside from hematopoietic stem cell transplantation, current approaches are non-curative, instead aiming to delay disease progression and manage cytopenias. The development of second-line therapies is a particularly urgent need. However, much research is underway to address this paucity of available options. Many new agents, targets, and treatment approaches are in development or under investigation, such as novel HMA-based combinations, immunotherapies including magrolimab and sabatolimab, and first-in-class agents like pevondenistat.
Researchers and clinicians from...2021-07-0839 minVJHemOnc PodcastEHA 2021: fixed-duration therapies and sequencing in CLLOver the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment combinations. One emergent strategy is fixed-duration therapy, which combines two or more agents for a set timeframe. Fixed-duration therapy is an appealing option for different reasons, including shorter treatment times and lower costs. Ongoing clinical trials investigating fixed-duration therapy combinations, such as ibrutinib-venetoclax, will help determine the best drug combination as well as the patient populations that will benefit the most. Another increasingly important topic in the CLL field is the optimal treatment selection and sequencing of therapies in...2021-07-0813 minVJHemOnc PodcastThe AML Sessions: Highlights from ASCO/EHA 2021Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine has gained importance in the treatment of AML, with important developments in gene mutation-targeted therapeutic agents transforming the treatment landscape. The role of measurable residual disease (MRD), an independent, postdiagnosis, prognostic indicator, in AML has been explored for many years. Still, the implementation of standardized MRD techniques remains critical for their use in clinical practice. Although the field has seen major therapeutic advances, novel agents, targets, and regimens continue to be investigated to offer patients a more promising outcome.2021-07-0743 minVJHemOnc PodcastEHA 2021: key trial updates in myelomaThe treatment and management of multiple myeloma has evolved drastically over the last ten years with the introduction of many novel drug classes and therapies, resulting in notable improvements in overall survival. However, many patients remain relapsed or refractory and thus clinical trials of novel agents and combinations are key to improving the outcomes of high-risk subgroups. In particular, there has been a rapid increase in the number of immunotherapies being trialled for myeloma patients, including monoclonal antibody and chimeric antigen receptor T-cell (CAR-T) therapies.
In this podcast, Saad Usmani, MD, MBBS, MBA, from the Levine Cancer...2021-07-0714 minVJHemOnc PodcastEHA 2021: MRD in myelomaOver the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall survival outcomes. The introduction of novel therapies has led to high levels of complete response, and many novel techniques are now being explored for the assessment of the depth of response, one of the most effective thus far being measurable residual disease (MRD). MRD describes a small number of cancer cells which remain after treatment but can only be detected by highly sensitive tests. MRD negativity has been demonstrated to be predictive of longer progression-free survival in a number...2021-06-2514 minOncology Knowledge into Practice PodcastHaematology series | ASCO and EHA conference specialAt the ASCO and EHA conferences, there were many interesting posters and presentations in the field of haemato-oncology. To share their conference highlights, we’ve invited our ALL expert Dr Dieter Hoelzer, director of internal medicine at the University of Frankfurt in Germany, and our MDS and AML expert Dr Amer Zeidan, Associate Professor Of Internal Medicine at the Yale University School Of Medicine in the US.
Funding statement:
This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty2021-06-2225 minVJHemOnc PodcastVJSession: EBMT/EHA CAR-T Nursing SessionThe 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European Haematology Association (EHA), and shed light on the current and future indications of CAR T-cell therapies in hematological oncology. The nursing program highlighted key questions in the management of patients treated with cellular therapies including communication within multidisciplinary teams, the use of immune effector cells in solid tumors, the importance of treatment settings as well as survivorship considerations following CAR T-cell therapy.
In this roundtable discussion, Erik Aerts of the Hematology Nurses and Healthcare Professionals Group, Winterthur...2021-02-2350 min
Motorkáři.czFilip Řeháček na tandemu s Vláďou: Moje cesta jde přes juniorské Mistrovství světaPáteční rozhovor bude tentokrát patřit závodníkovi Filipovi Řeháčkovi, který jezdí juniorské Mistrovství světa kategorie Moto3. Tento šampionát připravuje mladé jezdce pro Grand Prix a odehrává se převážně na španělských tratích. Poslechněte si Filipa, který vypráví o závodění na jihu Evropy, začátcích na motorce a plánech do další sezony.2021-01-1544 min
EHA - Encontro de História da Arte da Unicamp#11 - Sistemas de Escritura em Oaxaca: períodos pré-hispânico e colonialEntrevista com Ana Cristina de Vasconcelos Lima, doutoranda em História Social pela USP, que desenvolve a pesquisa “Sistemas de escritura em Oaxaca: períodos pré-hispânico e colonial inicial”, sob orientação do Prof. Dr. Eduardo Natalino dos Santos.
Roteiro e produção: Fernando Pesce, doutorando em História pela Unicamp.
Edição: Fernando Pesce
Imagem: Fólio 37a do Códice Vindobonensis. Pele de veado, estucada e pintada. Cultura Mixteca. Biblioteca Nacional de Áustria, Viena.2020-11-2130 min
EHA - Encontro de História da Arte da Unicamp#10 - Cor azul na História da ArteEntrevista com Valdriana Corrêa, mestranda em Artes Visuais pela UFRGS, desenvolve a pesquisa "Cromofobia X Cromofilia. A autonomia da cor e o triunfo do azul", sob orientação da profª. Dra. Daniela Pinheiro Machado Kern.
Roteiro e produção: Eugênia Pereira, mestranda em História pela Unicamp.
Edição: Eugênia Pereira
Imagem: Helena Almeida (1934 – 2018), "Pintura Habitada", 1976. Fotografia e tinta acrílica. Fundação Serralves, Cidade do Porto.2020-11-0718 min
The Emotionally Healthy Activist PodcastEHA Daily Arrow | Day 33: Processing the ElectionOn today's Daily Arrow, Media Production Coordinator for InterVarsity Media Production Coordinator, Kyle Lee, leads us through the book "Keeping the Faith: Reflections on Politics and Christianity" and invites us to process the results of the election in light of the Kingdom of God.
Be led through a time of contemplation, devotion, scripture, and prayer that helps interpret the world around you through the lens of Christ and Faith. This devotional was written by Jonathan Walton.
We're trying something different today! For a longer reflection guide, please check out Patreon.com/IVED to find our longer processing guide for today's...2020-11-0405 min
EHA - Encontro de História da Arte da Unicamp#9 - Arte Africana no Museu Nacional de Belas ArtesEntrevista com Gabrielle Nascimento Batista, doutoranda em História pela Unicamp, sob orientação da Prof.ª Dr.ª Juliana Ribeiro da Silva Bevilacqua, desenvolvendo a pesquisa “Arte ou Artefato? Um estudo da Coleção Africana do Museu Nacional de Belas Artes (MNBA-RJ)”.
Roteiro, produção e edição: Alysson Brenner, graduando em História pela Unicamp.
Imagem: Máscara Gueledé. Iorubá, Nigéria. Madeira, 43 x 37,5 x 40 cm. Sem assinatura. Compra: 1964, Gasparino Damata e Silva.2020-10-2425 min
EHA - Encontro de História da Arte da Unicamp#8 - O imaginário visual do cinema de horror italianoEntrevista com Letícia Badan Palhares Knauer de Campos, doutoranda no Programa de Pós-Graduação em História do Instituto de Filosofia e Ciências Humanas da Universidade Estadual de Campinas, com a pesquisa "O imaginário visual do cinema de horror italiano", sob orientação do Prof. Dr. Jorge Sidney Coli Junior
Roteiro, produção e edição: Ana Carolina Dias Florindo, mestranda em história pela Unicamp.2020-10-1138 min
EHA - Encontro de História da Arte da Unicamp#7 - Intervenção Urbana e a Sobrevivência da ImagemEntrevista com Thiago Spíndola Motta Fernandes, doutorando em Artes Visuais pela UFRJ, na linha de pesquisa História e Crítica da Arte, sob orientação da prof.ª Tatiana da Costa Martins, desenvolvendo a pesquisa: "Dentro-fora, público-privado: arte brasileira e os lugares do cotidiano"
Roteiro, produção e edição: Victória Cristina Rozario Rodrigues, graduanda em história pela Unicamp.
Imagem: FERRAZ, Guga. Ônibus Incendiado,2003.2020-09-2629 min
EHA - Encontro de História da Arte da Unicamp#6 - Cerâmica marajoara e a Amazônia por Manoel SantiagoEntrevista com João Augusto da Silva Neto, doutorando em História Social da Amazônia pela UFPA, sob orientação do prof. Aldrin de Figueiredo e desenvolvendo a pesquisa: "O artista colorista: um estudo sobre crítica, arte e criação artística em Manoel Santiago (1920-1986)".
Roteiro, produção e edição: João Brancato, doutorando em História pela Unicamp.
Imagem: Manoel Santiago: Tatuagem (detalhe), 1929. Óleo sobre tela, 195,5 x 130,87 cm. Museu de Arte de Belém, Pará.2020-09-1226 min
CCO Oncology PodcastApplication of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell LymphomaIn this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:ASPEN: Zanubrutinib vs ibrutinib in WMOASIS: Ibrutinib, venetoclax, and obinutuzumab in MCLGHSG HD17: PET-guided therapy in HLKEYNOTE-024: Pembrolizumab vs brentuximab in HLALEXANDER: AUTO3 in DLBCLPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer Institute2020-08-3135 min
EHA - Encontro de História da Arte da Unicamp#5 - Alair Gomes: A New sentimental JourneyEntrevista com Aline Gomes, doutoranda em história da arte pela Universidade Estadual de Campinas - UNICAMP (IFCH), desenvolvendo a pesquisa "Alair Gomes: A New sentimental Journey", com orientação pelo prof. Dr. Jorge Coli.
Roteiro e produção: Letícia Leme, mestranda em história pela Unicamp.
Edição: Letícia Leme.
Imagem:2020-08-2930 min
CCO Oncology PodcastApplication of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLLIn this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:ASCEND: acalabrutinib vs idelalisib plus rituximab or BRACE-CL-001: acalabrutinib long-term efficacyCLL14: Venetoclax plus obinutuzumabCLARITY: Ibrutinib plus venetoclaxMeasurable residual disease (MRD)Complex karyotypesZanubrutinib plus obinutuzumab and venetoclaxPresenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector...2020-08-2631 min
EHA - Encontro de História da Arte da Unicamp#4 - Diplomacia e arte para um Brasil modernoEntrevista com Breno de Faria, doutorando em Estética e História da Arte pela USP, desenvolvendo a pesquisa “Ars Diplomatica: o colecionismo de arte do Ministério das Relações Exteriores (1955-1970)”, com orientação pela prof. Dra. Ana Gonçalves Magalhães.
Roteiro e produção: Fanny Lopes, doutoranda em História pela Unicamp.
Edição: Fanny Lopes.
Imagem: Giorgi, Bruno. “O meteoro”. Palácio Itamaraty, Brasília. Fotografia por Marcel Gautherot, 1968. Negativo flexível, 6 x 6 cm. Instituto Moreira Salles (IMS).2020-08-1525 minVJHemOnc PodcastMPNs highlights at EHA 2020: clinical trials, novel therapies & pitfallsIt is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treatment options.
In this podcast, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Abdulraheem Yacoub, MD, of the University of Kansas Medi...2020-08-0611 min
EHA - Encontro de História da Arte da Unicamp#3 - Fazendo a reverência ao touroEntrevista com Érica Burini, mestranda em História pela Unicamp, desenvolvendo a pesquisa "Fazendo a reverência ao touro: um estudo das gravuras da Tauromaquia de Goya presentes no MASP". Com orientação da Profª. Patricia Dalcanale Meneses e financiamento da FAPESP.
Roteiro e produção: Eugênia Pereira, mestranda em História pela Unicamp.
Edição: Eugênia Pereira
Imagem: Francisco Goya y Lucientes, "Pepe Illo fazendo a reverência ao touro, da série Tauromaquia", 1815-16. Água-forte, 32,2 x 44,5 cm. Museu de Arte de São Paulo Assis Chateaubriand (MASP), São Paulo.2020-08-0111 min
EHA - Encontro de História da Arte da Unicamp#2 - Victor Meirelles e a "Questão Christie"Entrevista com Bárbara Fernandes, doutoranda em História pela UFJF, desenvolvendo a pesquisa "Representações de conflitos e silenciamentos na história da arte: análise da obra “Questão Christie” de Victor Meirelles". Orientação pela prof. Dra. Maraliz Christo e financiamento com bolsa da CAPES.
Roteiro e produção: João Brancato, doutorando em História pela Unicamp.
Edição: João Brancato,
Imagem: Meirelles, Victor. Estudo para “Questão Christie”, 1864. Óleo sobre tela. Museu Nacional de Belas Artes, Rio de Janeiro.2020-07-1820 min
HematocastNovidades em Mieloma Múltiplo: ASCO e EHANeste podcast, o Dr. Ricardo Helman e Dra. Mariana Kerbauy, hematologistas do Hospital Israelita Albert Einstein conversam sobre as novidades em Mieloma Múltiplo que foram apresentadas nos dois principais congressos do primeiro semestre deste ano: ASCO (Congresso Americano de Oncologia) e EHA ( Congresso Europeu de Hematologia).2020-07-1715 min
Lymphoma HubAn update in CLL from EHA 2020During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub spoke to Susan O'Brien, University of California Irvine, Orange, US, who discussed the latest updates on chronic lymphocytic leukemia (CLL) from EHA 2020.Highlights in CLL from this year's virtual EHA Annual Congress include1. Update (~39 months) from the CLL-14 trial (NCT02242942), comparing the safety and efficacy of obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL2. Update from the CAPTIVATE trial (NCT02910583) evaluating ibrutinib + venetoclax in patients with treatment-naïve CLL3. Acalabrutinib for the treatment of relapsed CLL...2020-07-1406 min
EHA - Encontro de História da Arte da Unicamp#1 - Representações da Antiguidade MayaEntrevista com Fernando Pesce, doutorando em História pela Unicamp, desenvolvendo a pesquisa "Representações da antiguidade Maya: Cultura Visual e ideologia na ilustração arqueológica (séculos XVI à XIX)".
Roteiro e produção: Letícia Leme, mestranda em História pela Unicamp.
Edição: Letícia Leme
Imagem: Catherwood, F. "Gateway at Labná", 1844. litografia colorida. Views of Ancient Monuments in Central America, Chiapas and Yucatan. plate XIX.2020-07-0820 minVJHemOnc PodcastKey updates in ALL at EHA 2020Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater understanding of the disease and treatment approaches, there can be better outcomes for patients. In this podcast, Carolina Vincente-Duenas from the Institute of Biomedical Research, Salamanca, Spain, Talha Badar of the Medical College of Wisconsin, Milwaukee, WI, and Christina Peters of St. Anna Children’s Hospital, Vienna, Austria, discuss key updates in ALL presented at this year’s virtual European Hematology Association (EHA) 2020 congress.
The post Key updates in ALL at EHA 2020 appeared first on VJHemOnc.
2020-07-0715 min
Blood & CancerEHA25: AML, myeloma, polycythemia vera, and COVID-19 with EHA President, John GribbenEHA25 highlights: EHA President John Gribben talks AML, myeloma, polycythemia vera, and COVID-19 What were the late-breaking and practice-changing presentations at EHA25 Virtual? John Gribben, MD, DSc, president of the European Hematology Association, highlighted some of them in this podcast. Dr. Gribben and host David H. Henry, MD, discussed presentations on acute myeloid leukemia (AML), multiple myeloma, polycythemia vera (PV), and COVID-19. Videos of these and other presentations will be available on the EHA25 website until Oct. 15. Randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs. azacitidine in treatment-naïve patients with acute my...2020-06-2528 min
Ka Piko PodcastKinai ʻEha: Josiah ʻĀkauFounded in 2017 by Josiah ʻĀkau KSK’96, Kinai ʻEha is a non-profit program that provides real-world vocational training, as well as life and workforce readiness skills for ʻōpio (youth) that are in dire need of and seeking purpose and direction. Kinai ʻEha means "to extinguish pain," and through the program, ʻōpio develop personal empowerment, Hawaiian cultural identity and leadership, earn a high school diploma and participate in community service and workforce training in the construction trades, adding to the vision of a thriving lāhui.2020-06-0438 min
Mix SessionEHAEHA by DjNosOfficial2020-02-241h 07
CoinTalk™️#49: 🎸 Senate Hearing Jam Session Pt. 2 w/ Brian Patrick Eha from Breaker MagazineBrian Patrick Eha, who has covered crypto lobbying for Breaker, calls in to talk about the Senate Hearings.
Part 1 here.
2018-10-1554 minVJHemOnc PodcastPatient discussion at EHA 2018: CAR T-cells and MRD in CLLCAR T-cells have demonstrated impressive efficacy in a variety of hematological malignancies, but their use in chronic lymphocytic leukemia (CLL) is still relatively new. In this podcast, Deborah Sims, CLL patient and advocate, and Brian Koffman, MD, CLL patient, and founder and medical director of the CLL society, discuss their experiences with the disease, and Brian’s recent treatment with CAR T-cells. They speak about their respective treatment routes, CAR T-cell toxicity and efficacy, the use of measurable residual disease (MRD) as an indicator of treatment success, and the future of CLL treatment. This discussion took place at the 23rd...2018-09-1411 min
Multiple Myeloma Research FoundationHighlights From the 2014 ASCO and EHA Annual MeetingsHighlights From the 2014 ASCO and EHA Annual Meetings, July 2014 - This program features expert physicians Meletios-Athanassios Dimopoulos, MD, from University of Athens in Athens, Greece, and Paul G. Richardson, MD, from the Dana-Farber Cancer Institute in Boston, MA. The presenters discuss and highlight major developments in myeloma research and treatments for newly diagnosed and relapsed/refractory disease stages.2014-07-0200 min
001Bonnies Creative Quilting Adventures VIDEO054Bonnies Creative Quilting Adventures - Beading Queen - Nancy EhaBonnie McCaffery, author of Portrait Quilts Painted Faces You Can Do, interviews Nancy Eha the Beading Queen.2011-01-0100 min
hwnmusiclives's PodcastNa Moku `EhaThe folks over at taropatch.net had been talking about this song and the fact that numerous Hawaiian songs utilize different melodies and chord structures but the same lyrics. ("Hi`ilawe" and "Kaimana Hila" come to mind among the many songs that have at least two different melodies.) It can be very confusing!
I was able to identify recordings of "Na Moku `Eha" employing as many as three different melodies and chord structures. So I very quickly threw together a montage of different versions of "Na Moku `Eha" so that all three different versions could be heard side...2007-07-1606 min